• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis.

作者信息

Wäsch Ralph, Strüssmann Tim, Wehr Claudia, Marks Reinhard, Meyer Phillip T, Walz Gerd, Engelhardt Monika

机构信息

Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstrasse 55, 79106, Freiburg, Germany.

Department of Nuclear Medicine, Medical Center - University of Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany.

出版信息

Ann Hematol. 2023 May;102(5):1269-1270. doi: 10.1007/s00277-023-05163-z. Epub 2023 Mar 17.

DOI:10.1007/s00277-023-05163-z
PMID:36930259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10102086/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c685/10102086/c20745dda838/277_2023_5163_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c685/10102086/c20745dda838/277_2023_5163_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c685/10102086/c20745dda838/277_2023_5163_Fig1_HTML.jpg

相似文献

1
Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis.在一名需要血液透析的多发性骨髓瘤患者中，针对B细胞成熟抗原（BCMA）进行安全且成功的嵌合抗原受体T细胞（CAR T）疗法。
Ann Hematol. 2023 May;102(5):1269-1270. doi: 10.1007/s00277-023-05163-z. Epub 2023 Mar 17.
2
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
3
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原免疫疗法对多发性骨髓瘤具有广阔的应用前景。
Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28.
4
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.一种针对复发或难治性多发性骨髓瘤的靶向 BCMA 和 CD38 的双特异性 CAR-T 细胞疗法。
J Hematol Oncol. 2021 Oct 9;14(1):161. doi: 10.1186/s13045-021-01170-7.
5
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.B 细胞成熟抗原是多发性骨髓瘤过继性 T 细胞治疗的一个有前途的靶点。
Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi: 10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.
6
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.同种异体嵌合抗原受体 T 细胞靶向 BCMA 治疗多发性骨髓瘤的临床前评估。
Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
7
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.GPRC5D 是一种经理性设计的 CAR T 细胞免疫疗法的多发性骨髓瘤的靶点。
Sci Transl Med. 2019 Mar 27;11(485). doi: 10.1126/scitranslmed.aau7746.
8
Optimizing the benefits of BCMA-targeted CAR T-cell therapy in multiple myeloma.优化靶向BCMA的嵌合抗原受体T细胞疗法在多发性骨髓瘤中的疗效
Clin Adv Hematol Oncol. 2023 Jan;21(1):43-45.
9
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.BCMA CAR-T 细胞疗法在多发性骨髓瘤中的安全性和临床疗效。
J Hematol Oncol. 2020 Dec 3;13(1):164. doi: 10.1186/s13045-020-01001-1.
10
Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.BCMA 靶向 CAR-T 免疫疗法治疗多发性骨髓瘤和复发性/难治性多发性骨髓瘤概述。
Scand J Immunol. 2020 Aug;92(2):e12910. doi: 10.1111/sji.12910. Epub 2020 Jun 17.

引用本文的文献

1
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.欧洲血液学年会-欧洲骨髓瘤网络关于多发性骨髓瘤患者诊断、治疗及随访的循证指南
Nat Rev Clin Oncol. 2025 Jul 7. doi: 10.1038/s41571-025-01041-x.
2
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing.双特异性抗体和嵌合抗原受体T细胞疗法在多发性骨髓瘤中的应用：患者的合理选择与治疗顺序
Mediterr J Hematol Infect Dis. 2025 May 1;17(1):e2025045. doi: 10.4084/MJHID.2025.045. eCollection 2025.
3
Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases.

本文引用的文献

1
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.针对包括透析患者在内的肾功能降低患者的 CD19 靶向嵌合抗原受体 T 细胞治疗的结果。
Transplant Cell Ther. 2022 Dec;28(12):829.e1-829.e8. doi: 10.1016/j.jtct.2022.09.009. Epub 2022 Sep 26.
2
Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis.在需要血液透析的患者中成功实施嵌合抗原受体（CAR）T细胞疗法。
Exp Hematol Oncol. 2022 Feb 28;11(1):10. doi: 10.1186/s40164-022-00266-1.
3
Novel immunotherapies in multiple myeloma - chances and challenges.
嵌合抗原受体（CAR）T细胞疗法在接受维持性血液透析的多发性骨髓瘤和肾衰竭患者中的应用：2例报告
Kidney Med. 2024 Jun 14;6(8):100856. doi: 10.1016/j.xkme.2024.100856. eCollection 2024 Aug.
4
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.伊达基奥仑赛嵌合抗原受体 T 细胞疗法治疗伴有肾功能损害的复发/难治性多发性骨髓瘤。
Haematologica. 2024 Mar 1;109(3):777-786. doi: 10.3324/haematol.2023.283940.
新型免疫疗法在多发性骨髓瘤中的应用——机遇与挑战。
Haematologica. 2021 Oct 1;106(10):2555-2565. doi: 10.3324/haematol.2020.266858.
4
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.欧洲骨髓瘤网络对 CAR T 细胞疗法治疗多发性骨髓瘤的看法。
Haematologica. 2021 Aug 1;106(8):2054-2065. doi: 10.3324/haematol.2020.276402.
5
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
6
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.抗 BCMA CAR T 细胞疗法 bb2121 治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.